SHEET 1 OF 1

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

	SHEET _L OF _L
ATTORNEY'S DKT NO.	APPLICATION NO.
033136-119	09/541,033
APPLICANT	
Richard G. Miller	
FILING DATE	GROUP
March 31 2000	1644

	5000 0000 0000 0000 0000 0000 0000 000							
		U	.S. PATENT DO	CUMENTS				
	U.S. Patent	Document				Ī		
Examiner		Kind Code	Name of Pater	ntee or Applicar	.+	Date of Bublic	- seisn	
Initials	Number	(if known)		Document	11	Date of Publication (MM-DD-YYYY)		
	T				,,,			
		†	M-1					
	 	-	<u> </u>					
l		1						
		1 1	· · · · · · · · · · · · · · · · · · ·					
	+	 		·· ·				
				· · · · · · · · · · · · · · · · · · ·				
		<u> </u>						
	-		w	· · · · · · · · · · · · · · · · · · ·				
	 							
		1			_			
	1	1					*****	
			EIGN PATENT D	OCUMENTS				
	Foreign Patent	Document						
Examiner		Kind Code			Da	ate of Publication	Translation	
Initials	Number	(if known)	Country		(MM-DD-YYYY)	Yes no	
		<u> </u>						
								
	 					·		├—
	 	 			<u> </u>			
		<u> </u>						
12		NON PAT	ENT LITERATUR	E DOCUME	NITC			
	Include							
Examiner	item (book.	name or aumor (m . magazine, journal.	CAPITAL LETTERS/	, title of the arti	cie (when	appropriate), title of the	e	
Initials		pı	ublisher, city and/or	country where t	iate, paye published.	(s), volume-issue nump	er(s),	i
	Genetic Engineering	News, "Companies	s Take Broad Range	of Approaches	to Develo	p Rheumatoid Arthritis	Therani	
OVIC	January 15, 1997,	Vol. 17, No. 2., pag	ge 1.				-	ies,
	Chen, Y.L., et al., ",	Anti-tumor necrosis	factor properties of	non-peptide dri	ugs in acu	ite-phase responses," E	ur. J.	-
	Pharmacol., Decemb	per 27, 1994, 271:	(2-3), pp. 319-327.	Abstract C	only		ui. u.	
					0			
					-			
								
				-				
				η				
Examiner	I how			Date	,,,,,	•		
Signature (110m			Considered	2/19/	50		

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.